---
title: "Gracell Biotechnologies Shareholders Approve AstraZeneca Merger Agreement"
description: "Gracell Biotechnologies shareholders have approved a merger agreement with AstraZeneca. The agreement involves the execution, delivery, and performance of the merger, with Gracell becoming a wholly ow"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/108247711.md"
published_at: "2024-02-20T13:00:42.000Z"
---

# Gracell Biotechnologies Shareholders Approve AstraZeneca Merger Agreement

> Gracell Biotechnologies shareholders have approved a merger agreement with AstraZeneca. The agreement involves the execution, delivery, and performance of the merger, with Gracell becoming a wholly owned subsidiary of AstraZeneca. The approval was granted by 99.9% of the total votes cast at the meeting.

Gracell Biotechnologies Inc. (("Gracell" or the "Company", NASDAQ:GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the "EGM") held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the "Merger Agreement"), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales ("Parent"), and Grey Wolf Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent ("Merger Sub"), the Plan of Merger required to be filed with the Registrar of Companies of the Cayman Islands (the "Plan of Merger"), and the other agreements or documents contemplated by the Merger Agreement or any document or instrument delivered in connection thereunder (the "Transaction Documents") to which the Company is a party and the consummation of the transactions contemplated by the Merger Agreement (including the Merger) and the Contingent Value Rights Agreement, in the form attached as Exhibit B to the Merger Agreement, (collectively, the "Transactions"), upon the terms and subject to the conditions set forth therein. Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the "Merger").

At least 458,283,333 of the Company's total outstanding ordinary shares, par value of $0.0001 per share ("Ordinary Shares"), including Ordinary Shares represented by the Company's American Depositary Shares (the "ADSs"), attended the EGM in person or by proxy. Each shareholder has one vote for each Ordinary Share. These shares represented approximately 94.8% of the total outstanding votes represented by the Company's total Ordinary Shares outstanding at the close of business in the Cayman Islands on the record date of January 8, 2024. The Merger Agreement, the Plan of Merger and the Transactions, were approved by approximately 99.9% of the total votes cast at the EGM.

### Related Stocks

- [AZN.US - AstraZeneca](https://longbridge.com/en/quote/AZN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 中國白銀集團 (0815) 折讓 18% 配股籌 4.6 億 | 中國白銀集團宣佈將向 6 名認購人發行 9.1 億股認購股份，折讓約 17.74%，每股認購價為 0.51 元，籌集資金總額為 4.641 億元。所得款項將用於日喀則礦的資本開支、進一步融資及一般營運資金。 | [Link](https://longbridge.com/en/news/276432450.md) |
| 打響改善空污持久戰 中國改善空污成就非凡 | 中國在改善空氣品質方面取得顯著成就，尤其是北京的空氣汙染情況有了明顯改善。根據北京市政府數據，自 2013 年以來，PM2.5 濃度下降了 69.8%。儘管仍有城市的汙染水平高於世界衞生組織標準，但整體空氣品質已大幅提升。公眾意識的提高和政 | [Link](https://longbridge.com/en/news/276113731.md) |
| 阿斯利康稱，美國 FDA 已批准 Calquence 組合療法用於特定血癌患者 | 阿斯利康表示，美國 FDA 批准 Calquence 聯合療法用於某些血癌患者 | [Link](https://longbridge.com/en/news/276444179.md) |
| 安大略教師養老金計劃委員會出售了阿斯利康公司（AstraZeneca PLC）的$AZN 股票 | 安大略教師退休金計劃委員會在第三季度將其在阿斯利康（AstraZeneca PLC，NASDAQ:AZN）的持股減少了 41%，目前持有 817,880 股，價值 6270 萬美元。其他機構投資者也調整了他們的持倉，加拿大帝國商業銀行世界市 | [Link](https://longbridge.com/en/news/276339476.md) |
| Select 醫藥控股｜10-K：2025 財年營收 54.53 億美元超過預期 |  | [Link](https://longbridge.com/en/news/276384073.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
